Table 1 Demographic characteristics of 100 patients with HER2-positive breast cancer

From: Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies

 

N =100

Age, median (range)

55 (22–82)

ECOG performance status

0

20

1

75

2

5

Menopausal status

Premenopausal

40

Postmenopausal

60

Hormone receptor status

ER(+)/PR(+), ER(+)+PR(+)

59

ER(−)/PR(−)

41

HER2 status

HER2 IHC 3+

94

HER2 IHC 2+, FISH+

6

Number of metastatic sites

1

54

2

26

⩾3

20

Metastatic site

Visceral organs

64

Non-visceral organs

36

Histology

Invasive ductal

98

Invasive ductal+lobular

2

Tumour grade

Grade 1

2

Grade 2

40

Grade 3

58

  1. Abbreviations: ECOG=Eastern Cooperative Oncology Group; ER=estrogen receptor; FISH=fluorescence in situ hybridization; IHC=immunohistochemistry; PR=progesterone receptor.
Back to article page